Bioinformatics expansion strengthens our metagenomics solutions
We’ve launched a new metagenomics analysis plugin for our QIAGEN CLC Genomics ProSuite and CLC Genomics Workbench. Developed by CosmosID, the plugin is particularly helpful for those working with complex metagenomics samples, when identifying genes involved in virulence or antibiotic resistance, for example, is crucial.
Here you can find the full press release about this release.
QIAGEN and CosmosID launch new plugin for metagenomics analysis
QIAGEN and CosmosID, a leading genomic big data company, today announced the launch of a metagenomics analysis plugin for the QIAGEN CLC Genomics ProSuite and CLC Genomics Workbench. The launch of the Cosmos ID plugin expands QIAGEN’s industry leading platform for NGS bioinformatics and strengthens its role as a provider of Sample to Insight metagenomics solutions.
The CosmosID plugin offers support for shotgun metagenomics and microbiome profiling for application in the fields of infectious disease, food safety, animal health, agriculture, and environmental analysis.
“The addition of the CosmosID plugin to the QIAGEN CLC Genomics ProSuite brings researchers a truly comprehensive package of metagenomics and microbiome profiling applications that we now have conveniently integrated into a single, user friendly and scalable software environment,” said Laura Furmanski, Senior Vice President of QIAGEN’s Bioinformatics business area. “When working with complex metagenomics samples, accurately identifying pathogens and identifying genes involved in virulence or antibiotic resistance is crucial. Achieving this requires a combination of precision algorithms and highly curated content in reference databases. With the CosmosID plugin, QIAGEN users gain access to both, algorithms and databases.”
“The CosmosID plugin enables researchers to profile microbial communities fast, accurately and with strain level resolution. Results of comparative analyses of datasets are visually accessible in heat maps and principal component analysis plots,” said Manoj Dadlani, CEO of CosmosID. “They start with raw sequencing data, use CosmosID for microbial identification and comparison, and QIAGEN bioinformatics for functional analysis. It’s a complete workflow and a natural fit by which these tools can be integrated.”
Metagenomics is a field of great interest and focus for QIAGEN. The company has built strong leadership positions from sample through the analysis. The market for metagenomics and microbiome research is currently growing at over 20%. QIAGEN delivers a range of specialized solutions guiding microbiome researchers from sample to insight. With delivering integrated and user friendly bioinformatics QIAGEN is addressing one of the major bottlenecks in the metagenomics workflow. To learn more about QIAGEN’s offering in microbiome research, click here.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.
CosmosID®, based in Rockville, Maryland, is a genomics big data company focused on rapid identification of microorganisms for molecular diagnostics, public health, food safety, agriculture, and environmental applications. The CosmosID platform uses proprietary sequence analysis algorithms to accurately profile all microorganisms in a metagenomic sample employing next-generation DNA sequencing. To learn more please visit www.cosmosid.com.